Latest Commercial Expansion News

Memphasys will receive an A$3.5 million advance from major shareholder Peters Investments to expand Felix production, inventory and sales capacity as repeat orders emerge across international markets. The funding carries a 12.5% interest rate, potential equity dilution and requires shareholder and ASX approvals before the convertible notes can be issued.

MyEco Group is seeking up to $1.5 million through a discounted, non-underwritten share purchase plan to expand council and waste management sales, retail distribution and its eco-home range. The final issue price and amount raised remain uncertain, with the company retaining the option to scale up the offer or pursue a follow-on placement.

EBR Systems plans to file a Changes Being Effected PMA supplement in the fourth quarter to make echo-induced pacing risks and their mitigations more prominent on WiSE System labelling. The FDA has aligned with the proposed path, but the filing and final labelling changes are still ahead.

Dataworks has secured firm commitments for a A$3.0 million placement and will seek up to a further A$1.24 million from shareholders to fund debt repayment, government contract mobilisation and commercial expansion. The raise gives the company more capital to pursue growth, but at a discount that will increase the share count and potentially add substantial option dilution.

Sparc Technologies has made its inaugural commercial delivery of ecosparc®, a graphene additive, to a major coatings manufacturer, underpinning its push to dominate the protective coatings market. The company also launched a discounted Share Purchase Plan to fuel ongoing commercial expansion.

Recce Pharmaceuticals narrowed its operating loss to AUD 15 million in FY26, progressing Phase 3 trials for its anti-infective RECCE 327 and securing key patents and commercial partnerships.

Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.

First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.